Navigation Links
UBC researchers design new biomaterial that mimics muscle elasticity
Date:5/5/2010

University of British Columbia researchers have cast artificial proteins into a new solid biomaterial that very closely mimics the elasticity of muscle.

The approach, detailed in the current issue of the journal Nature, opens new avenues to creating solid biomaterials from smaller engineered proteins, and has potential applications in material sciences and tissue engineering.

"There are obvious long-term implications for tissue engineers," says Hongbin Li, associate professor in the Dept. of Chemistry. "But at a fundamental level, we've learned that the mechanical properties we engineer into the individual proteins that make up this biomaterial can be translated into useful mechanical properties at the larger scale."

Li, Canada Research Chair in Molecular Nanoscience and Protein Engineering, and UBC colleague John Gosline, professor in the Dept. of Zoology, engineered the artificial proteins to mimic the molecular structure of titin.

Titin also known as connectin is a giant protein that plays a vital role in the passive elasticity of muscle. The engineered version-which resembles a chain of beads-is roughly 100 times smaller that titin.

The resulting rubber-like biomaterial showed high resilience at low strain and was tough at high strain features that make up the elastic properties of muscles.

"A hallmark of titin-like proteins is that they unfold under a stretching force to dissipate energy and prevent damage to tissues by over-stretching," says Gosline. "We've been able to replicate one of the more unique characteristics exhibited by muscle tissues, but not all of them."

The mechanical properties of these biomaterials can be fine-tuned, providing the opportunity to develop biomaterials that exhibit a wide range of useful properties including mimicking different types of muscles. The material is also fully hydrated and biodegradable.


'/>"/>

Contact: Chris Balma
balma@science.ubc.ca
604-822-5082
University of British Columbia
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the Living Planet Symposium have been hearing about ... almost three months, the satellite is in excellent health ... presented at the symposium. Prof. Duncan Wingham, Lead ... in very good shape exceeding in-orbit specifications, the ...
... protein that helps pack DNA into the cell nucleus has ... researchers found that the protein, histone H1, also takes part ... all proteins are made. The study appeared online May ... A human cell,s genetic material is so vast that it ...
... of the extinction of woolly mammoths and other large mammals ... fallen victim to the same type of "trophic cascade" of ... the global decline of predators such as wolves, cougars, and ... originally begun by human disruption of ecosystems, a new study ...
Cached Biology News:CryoSat-2 exceeding expectations 2Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 2'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 3'Trophic cascades' of disruption may include loss of woolly mammoth, saber-toothed cat 4
(Date:3/4/2015)... Korea , March 4, 2015 Vegalab ... company, in August of last year. As part of ... Kyung Bon Koo continuing his role as CEO ... President of Vegalab S.A., will work alongside Koo and ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 Koo ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... of the "Gene Therapy Market, 2015 - 2025" ... "Gene Therapy Market, 2015-2025" report provides an extensive study ... of research has been carried out in this field ... approved therapies (four available in Asian markets; one approved ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
... Aug. 7 Kensey Nash Corporation today announced an ... along with the trademark, inventory and other assets associated ... the terms of the agreement, the Company and Biomet ... agreement. Pursuant to the agreement, following a brief transition ...
... , , SAN MATEO, Calif., Aug. ... , , , Granted ... non-diabetic adults, either alone or in combination with other medicinal products for pain ... (Astellas) for commercialization of Qutenza in Europe, Middle East and Africa, including commercialization ...
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
Cached Biology Technology:Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3NeurogesX Reports Second Quarter 2009 Results 2NeurogesX Reports Second Quarter 2009 Results 3NeurogesX Reports Second Quarter 2009 Results 4NeurogesX Reports Second Quarter 2009 Results 5NeurogesX Reports Second Quarter 2009 Results 6NeurogesX Reports Second Quarter 2009 Results 7NeurogesX Reports Second Quarter 2009 Results 8NeurogesX Reports Second Quarter 2009 Results 9NeurogesX Reports Second Quarter 2009 Results 10NeurogesX Reports Second Quarter 2009 Results 11NeurogesX Reports Second Quarter 2009 Results 12Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4